StreetInsider.com News Articles

BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha

Fri, 09 Oct 2026 15:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today issued a statement regarding a Notice of Civil Claim ("Claim") filed against the Company by Steven Sangha, an independent director of BetterLife, in the Supreme Court of British Columbia on October 8, 2026.

As disclosed in the Company's unaudited interim financial statements and management's discussion and analysis for July 2026, filed on SEDAR+ on September 29, 2026, a dispute arose between the Company and Dr. Sangha regarding the repayment of the principal amount of a convertible debenture issued

BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha

Fri, 09 Oct 2026 15:00:00 -0400

BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha

Fri, 09 Oct 2026 15:00:00 -0400

BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha

Fri, 09 Oct 2026 15:00:00 -0400

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

Tue, 29 Sep 2026 17:59:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, today announced that its upcoming Annual General Meeting ("AGM"), originally scheduled for October 14, 2026, has been rescheduled and reclassified as an Annual General and Special Meeting ("AGSM"). The rescheduled meeting will now take place on December 9, 2026 at 10am PT via conference call.

Reason for Reclassification

The Board of Directors made the decision to change the meeting format to include special business matters that

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

Tue, 29 Sep 2026 17:59:00 -0400

Reason for Reclassification

The Board of Directors made the decision to change the meeting format to include special business matters that

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

Tue, 29 Sep 2026 17:59:00 -0400

Reason for Reclassification

The Board of Directors made the decision to change the meeting format to include special business matters that

BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting

Tue, 29 Sep 2026 17:59:00 -0400

Reason for Reclassification

The Board of Directors made the decision to change the meeting format to include special business matters that

Form SCHEDULE 13G BetterLife Pharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 22 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260922/27091073.html

Form SCHEDULE 13G BetterLife Pharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 22 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260922/27091073.html

Form 6-K BetterLife Pharma Inc. For: Sep 14

Tue, 15 Sep 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260915/27063728.html

Form 6-K BetterLife Pharma Inc. For: Sep 14

Tue, 15 Sep 2026 12:11:00 -0400

si-local-file:///var/storage/secattach/20260915/27063728.html

Form 6-K BetterLife Pharma Inc. For: Sep 11

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050463.html

Form 6-K BetterLife Pharma Inc. For: Sep 11

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050463.html

BetterLife Pharma names Charles Duncan as director and audit chair

Mon, 31 Aug 2026 08:02:11 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) has appointed Charles Duncan, PhD, as a director and chair of its audit committee, the Vancouver-based biotechnology company announced.

Dr. Duncan has nearly 30 years of experience in the biopharmaceutical industry, including roles as a biotechnology analyst at Cantor Fitzgerald, Piper Jaffray and JMP Securities. During his Wall Street career, he initiated research coverage on more than 175 biotechnology companies, evaluated over 200 investment banking transactions and served as senior vetting analyst on approximately 25 initial public offerings.

He currently serves as Managing Director and Head of Biotech Strategy and Development at Gilmartin

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Mon, 31 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of Charles Duncan, PhD as Director and Chair of the Audit Committee.

Dr. Duncan is a biotechnology strategist, board director and former top-ranked Wall Street biotechnology analyst with nearly 30 years of experience advising investors, management teams and boards across the biopharmaceutical industry. As Managing Director, Head of Biotech Strategy & Development at Gilmartin Group, he provides strategic advisory and

BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee

Mon, 31 Aug 2026 08:00:00 -0400

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

Form 6-K BetterLife Pharma Inc. For: Aug 24

Mon, 24 Aug 2026 10:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26965496.html

BetterLife Pharma names neurologist as chief medical officer

Wed, 19 Aug 2026 08:02:10 -0400

BetterLife Pharma Inc. (CSE: BETR, OTCQB: BETRF, FSE: NPAU) has appointed Mahan Chehrenama, DO, as Chief Medical Officer, according to a company statement. Dr. Chehrenama will lead clinical development for BETR-001, the company's non-hallucinogenic neuroplastogen candidate targeting migraine and other headache disorders.

The Vancouver-based biotechnology company is working toward an Investigational New Drug (IND) application for BETR-001, anticipated in the first quarter of 2027.

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist with more than two decades of clinical practice. She most recently served as Chief Medical Officer at Manistee Therapeutics, where she led an IND submission and oversaw Phase 1

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) application for migraine and other headache disorders, anticipated in the first quarter of 2027.

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist who pairs nearly a decade in senior biopharma drug development with more than two decades of clinical practice and research

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Dr. Chehrenama is a board-certified neurologist and headache sub-specialist who pairs nearly a decade in senior biopharma drug development with more than two decades of clinical practice and research

Form 6-K BetterLife Pharma Inc. For: Aug 03

Wed, 05 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26869401.html

Form 6-K BetterLife Pharma Inc. For: Aug 03

Wed, 05 Aug 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260805/26869401.html